MedPath

Effects f mirtazapine and gabapentin in treatment of uremic pruritus

Phase 3
Conditions
Chronic kidney disease.
Chronic kidney disease (CKD)
Registration Number
IRCT20150629022965N20
Lead Sponsor
Hamedan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

aged above 18
diagnosis of end stage renal disease
receiving dialysis 3 times a week
no history of dermatological disorder which result in feeling itch
no history allergen medications or foods
no history of receiving medication which relieve itch
presence of moderate, severe and very severe pruritus

Exclusion Criteria

pregnancy or lactation
presence of liver failure
presence of any psychiatric disorder
hyperfosfatemia
diabetic neuropathy

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Severity of pruritus based on Visual analogue scale. Timepoint: daily for 5 weeks. Method of measurement: Visual analogue scale (VAS).
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath